Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · IEX Real-Time Price · USD
15.14
+1.04 (7.38%)
May 3, 2024, 4:30 PM EDT - Market closed
Gyre Therapeutics Revenue
In the year 2023, Gyre Therapeutics had annual revenue of $113.45M with 10.91% growth. Revenue in the quarter ending December 31, 2023 was $113.45M with 11.78% year-over-year growth.
Revenue (ttm)
$113.45M
Revenue Growth
+10.91%
P/S Ratio
11.41
Revenue / Employee
$191,315
Employees
593
Market Cap
1.29B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 113.45M | 11.16M | 10.91% |
Dec 31, 2022 | 102.29M | 94.95M | 1,293.98% |
Dec 31, 2021 | 7.34M | -13.61M | -64.97% |
Dec 31, 2020 | 20.95M | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 1.02M | 619.00K | 155.14% |
Dec 31, 2016 | 399.00K | -1.35M | -77.20% |
Dec 31, 2015 | 1.75M | -63.00K | -3.47% |
Dec 31, 2014 | 1.81M | 1.29M | 246.65% |
Dec 31, 2013 | 523.00K | -57.34M | -99.10% |
Dec 31, 2012 | 57.86M | -39.78M | -40.74% |
Dec 31, 2011 | 97.64M | 11.92M | 13.91% |
Dec 31, 2010 | 85.71M | 60.65M | 242.00% |
Dec 31, 2009 | 25.06M | 4.98M | 24.78% |
Dec 31, 2008 | 20.09M | 8.51M | 73.51% |
Dec 31, 2007 | 11.58M | -15.96M | -57.96% |
Dec 31, 2006 | 27.54M | 26.36M | 2,233.81% |
Dec 31, 2005 | 1.18M | -2.56M | -68.44% |
Dec 31, 2004 | 3.74M | 1.28M | 52.07% |
Dec 31, 2003 | 2.46M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AdaptHealth | 3.20B |
Alignment Healthcare | 2.01B |
Agiliti | 1.17B |
Pacira BioSciences | 674.98M |
Ironwood Pharmaceuticals | 442.74M |
4D Molecular Therapeutics | 20.72M |
Spyre Therapeutics | 886.00K |
GYRE News
- 5 weeks ago - Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum - GlobeNewsWire
- 2 months ago - INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 3 months ago - IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 3 months ago - INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 3 months ago - SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 5 months ago - Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding - PRNewsWire
- 6 months ago - Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting - GlobeNewsWire